Abstract
Opportunistic fungal infections are a major cause of morbidity and mortality in immunosuppressed patients; and in HIV-positive individuals, infections due to Candida, Cryptococcus, and Pneumocystis are AIDS-defining illnesses. The widespread use of antifungal drugs, particularly triazole drugs, has led to the emergence of primary resistance, which largely reflects infection with inherently less susceptible strains. Secondary resistance in normally susceptible strains also occurs and involves a variety of mechanisms including target site modification and drug efflux transporters. Resistance is a clinical management issue, but it has remained relatively constant in most developed countries. In developing countries, resistance is minimal due to limited antifungal therapy. However, as access to these drugs increases, it is particularly important to evaluate trends that reflect evolving resistance issues observed elsewhere, especially among individuals with HIV/AIDS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.